Epicatechin

Epicatechin: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

(–)-Epicatechin is a type of compound known as a flavonoid, specifically a flavan-3-ol. Its systematic chemical name is (2R,3R)-3,3′,4′,5,7-flavanpentol. The biologically predominant naturally occurring form is the (–) enantiomer, designated (–)-epicatechin or (2R,3R)-epicatechin. A separate enantiomer, (+)-epicatechin, also occurs naturally in certain plant sources but is less abundant and has distinct properties. Epicatechin (referred to as "(–)-epicatechin," or "minus epicatechin" when found in foods) is a bioactive found in a distinct subgroup of flavonoids called flavanols.

Unlike the flavonol quercetin, having the same number and positions of hydroxyl groups, in (–)-epicatechin the double bond systems of the three rings (A, B and C) are not conjugated with each other, which gives rise to distinct chemical and biological properties. A significant consequence of this structure is that (–)-epicatechin exhibits less prooxidant and cytotoxic properties at high concentrations than quercetin, because the high degree of conjugation of the double bonds enables quercetin to be oxidized to an array of quinoid oxidation products, which cannot be expected to such an extent with (–)-epicatechin or related flavan-3-ols.

Stereoisomers

Epicatechin exists as two enantiomers with significantly different botanical distributions. (+)-Epicatechin is a naturally-occurring product found in guarana, grapes, chocolate and tea. The (–) form is the predominant isomer found in cocoa and most commonly studied plant sources. Release specifications for pharmaceutical-grade preparations require >90% purity, with <5% of the enantiomer and 5% of catechin. The absolute stereochemistry of (–)-epicatechin is established because it is either isolated from natural sources and further purified, or it is synthesized and compared to the natural isomer.

Relationship to Related Compounds

Both epicatechin and EGCG (epigallocatechin gallate) are catechins found in green tea and other plant sources, but they have some distinct differences: epicatechin is simpler than EGCG, which has an additional galloyl group. This structural difference affects their properties and how they interact with the body. While both are present in green tea, epicatechin is more abundant in cocoa, while EGCG is the predominant catechin in green tea.

2. Natural Sources and Distribution

(–)-Epicatechin (EC) is a flavanol easily obtained through the diet and is present in tea, cocoa, vegetables, fruits, and cereals.

Epicatechins are found primarily in both green tea and black tea, the most commonly consumed beverage globally. Cacao has the highest epicatechin content, followed by broad bean pod, having mean epicatechin content of 70.36 mg/100 g F.W. and 37.55 mg/100 g F.W., respectively. Additionally, epicatechin is found in smaller concentrations in berries and most of the regularly consumed fruits, chocolates and non-alcoholic beverages.

Catechins and epicatechins are found in cocoa, which, according to one database, has the highest content (108 mg/100 g) of catechins among foods analyzed, followed by prune juice (25 mg/100 ml) and broad bean pod (16 mg/100 g).

Green tea is produced from the shrub Camellia sinensis and has more epicatechin compared to black tea because black tea undergoes oxidative polymerisation during fermentation. Whereas, green tea is an unfermented product and retains 90% of its flavanols during steaming of its fresh leaves. The addition of milk can interfere with the absorption of epicatechins and other important flavonols, which is why dark chocolate is the superior option in terms of health effects.

Additional dietary sources include: green and black tea, red wine, ginger, fava beans, and blackberries. The taste associated with monomeric (+)-catechin or (–)-epicatechin is described as slightly astringent, but not bitter.

3. Common Supplement Forms and Preparations

Epicatechin is commercially available in several forms. In research settings, (–)-epicatechin is obtained from tea extracts and purified in GMP facilities by dissolving in ethanol, treating with charcoal, filtering to remove insolubles, exchanging the solvent to purified water, and then removing the solvent by lyophilization. This lyophilized (–)-epicatechin has been demonstrated to be stable for at least six months under refrigeration.

For dietary supplement use, effective studied doses range from 25–200 mg per day, with cacao-derived epicatechin typically standardized to 90–95% purity in supplement form. Epicatechin is also available as cocoa extract standardized for flavanol content. Epicatechin may also be provided in the form of a plant extract which naturally already contains substantial levels of epicatechin, with preferred extracts being from apple, cocoa, or tea.

(+)-Epicatechin is not commercially available in current Good Manufacturing Practices (GMP) grade monomeric form for any purpose, research or otherwise. Cardero Therapeutics has developed the first scalable manufacturing process that provides pharmaceutical grade (+)-epicatechin.

4. Traditional and Historical Use

Historically, cacao beans were used by Mesoamerican civilizations as part of rituals and for perceived energizing effects. Traditional Chinese tea culture prized green tea leaves, though ancient texts focused on overall tea quality rather than specific catechins. It is important to note that ancient and traditional medical systems did not identify or isolate epicatechin as a compound; they worked with whole plant preparations in which epicatechin was an unrecognized constituent.

In Ayurveda, classical texts like Charaka Samhita do not mention "epicatechin" by name; rather, they highlight the rasa (taste) and virya (potency) of foods like tea and unroasted grains, describing their digestive-stimulating or detoxifying qualities. In medieval Europe, herbalists used grape seed extracts without isolating epicatechin, but noted cardiovascular tonic properties.

Cacao as a beverage has a particularly deep history in Mesoamerican cultures. According to Norman Hollenberg, professor of medicine at Harvard Medical School, (–)-epicatechin can reduce the risk of four of the major health problems: stroke, heart failure, cancer and diabetes. He studied the Kuna people in Panama, who drink up to 40 cups of cacao a week, and found that the prevalence of these conditions is less than 10%. This epidemiological observation, though not demonstrating causation and subject to significant confounding, has driven much of the modern interest in epicatechin.

Discovery and Isolation

The first isolation of epicatechin dates back to the early 1930s when chemists studying tea polyphenols identified a set of catechins. The (–) stereoisomer was distinguished in the 1950s by stereochemical analysis. By the 1990s, cardiovascular researchers began linking cocoa consumption to improved endothelial function, prompting a surge of interest in epicatechin as the active component.

5. Active Compounds and Mechanisms of Action

Endothelial Nitric Oxide Signaling

The vascular effects of (–)-epicatechin appear to result from increased plasma nitric oxide (NO) and activation of endothelial nitric oxide synthase (eNOS). While (–)-epicatechin has well-characterized antioxidant properties, its ability to activate and induce NO in vascular endothelium and other tissues distinguishes it from other antioxidants and appears to be the therapeutically significant mechanism of action.

When (–)-epicatechin is administered at increasing doses (0.1–1 µM) to cultured human endothelial cells, a progressive release of nitric oxide (NO) occurs secondary to the activation of eNOS, peaking by 10 minutes and plateauing at 1 µM. This effect is associated with biochemical signaling changes indicating cell membrane-mediated responses. When (–)-epicatechin is given repeatedly over periods of up to several days, an upregulation in eNOS protein levels occurs, indicating enhanced capacity to produce NO for a given stimulus.

The intracellular signaling cascade involved has been further characterized: research suggests epicatechin stimulates eNOS phosphorylation through the PI3K/Akt signaling cascade, increasing the production of nitric oxide in endothelial cells. This mechanism of eNOS activation through PI3K/Akt-dependent phosphorylation supports NO bioavailability without direct NOS transcription upregulation. This pathway is distinct from classical pharmacological NO donors and represents a physiologically consistent mechanism of vascular modulation.

The activity of (–)-epicatechin in endothelial cells modulates eNOS in a favorable direction by preventing proteasome-mediated loss of eNOS protein due to oxidatively modified LDL, with concomitant protection of endothelial cells against oxidized LDL-mediated cell death, and by ameliorating endothelial nitric oxide production at the posttranslational level. Research concludes that (–)-epicatechin contributes to protecting the integrity of endothelial cells not only by scavenging free radicals but also by maintaining endothelial NO synthase.

Antioxidant Activity

EC has been shown to activate Nrf2, enhance the expression of antioxidant enzymes, and inhibit oxidative stress-induced inflammation. EC acts both directly—via suppression of NF-κB, mitogen-activated protein kinase (MAPK), and JAK/STAT pathways—and indirectly through activation of Nrf2-driven antioxidant responses that mitigate inflammatory damage.

These compounds reportedly act as free radical scavengers and inhibitors of eicosanoid biosynthesis; in model systems, they also reduce low-density lipoprotein oxidation, prevent platelet aggregation, and protect the heart from ischemia injury. (–)-Epicatechin in cacao quenches hydroxyl radicals 100 times more effectively than mannitol, a typical hydroxyl radical scavenger.

Myostatin / Follistatin Pathway

Myostatin is a myokine ("muscle-derived hormone") that inhibits excess muscle growth by reducing the expression of myogenic factors. When myostatin binds to its receptor, ActRIIB, it activates a cellular pathway called Smad that blocks genes from transcribing myogenic factors.

The specific flavanol (–)-epicatechin has been identified in rodent studies to increase nitric oxide production, increase mitochondrial biogenesis, increase angiogenesis, decrease myostatin, increase follistatin, and increase exercise performance.

Systematic review has demonstrated a commonness of epicatechin's inhibitory action on myostatin expression and atrogenes MAFbx, FOXO, and MuRF1. Epicatechin has shown positive effects on follistatin and on the stimulation of factors related to myogenic actions (MyoD, Myf5, and myogenin).

Mitochondrial Biogenesis

The literature shows that epicatechin can interfere with mitochondrial biosynthesis in muscle fibers, stimulation of the signaling pathways of AKT/mTOR protein production, and amelioration of skeletal musculature performance, particularly when combined with physical exercise.

Anti-Inflammatory Pathways

A recent review summarized the absorption, distribution, metabolism, and excretion characteristics and molecular mechanisms through which EC modulates inflammation. EC acts both directly—via suppression of NF-κB, MAPK, and JAK/STAT pathways—and indirectly through activation of Nrf2-driven antioxidant responses that mitigate inflammatory damage.

Fibrinolytic and Coagulation Effects

Incubation of platelet-poor plasma with epicatechin was shown to increase fibrin clot permeability, promoting sensitivity to tPA and enhancing breakdown of the clot. Another study with low concentrations (1–10 µM) of epicatechin showed positive effects on fibrin clot formation in platelet-poor plasma. Catechins without a galloyl group (catechin, epicatechin) or with a galloyl group in the 2′ position (epigallocatechin) did not inhibit platelet aggregation, in contrast to galloylated catechins such as EGCG.

6. Scientific Evidence by Area of Application

6.1 Cardiovascular Health and Endothelial Function

Epidemiological evidence: Epidemiological studies indicate an inverse relationship between flavanol intake and the risk of cardiovascular disease. A meta-analysis of interventional and observational studies encompassing approximately 114,000 subjects reported that the highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular disease (relative risk 0.63, 95% CI 0.44 to 0.90) and a 29% reduction in stroke compared with the lowest levels. However, such studies do not isolate epicatechin from other dietary variables.

Mechanistic human studies: Results from human trials indicate that (–)-epicatechin elicits beneficial effects on the vascular system. Acute administration of 200 mg of (–)-epicatechin resulted in the augmentation of nitric oxide production and reduced endothelin-1, a marker of oxidative stress, in healthy men. Similar results were reported for nitric oxide production in healthy males after ingestion of (–)-epicatechin-rich cocoa.

Blood pressure: (–)-Epicatechin-containing foods have a blood pressure-lowering capacity. The mechanisms underlying (–)-epicatechin action may help prevent oxidative damage and endothelial dysfunction, which have both been associated with hypertension. Human randomized controlled trials (RCTs) show that catechins impart significant blood pressure lowering effects. Mechanistically, flavonoids mediate their antihypertensive effects through increasing nitric oxide (NO) bioavailability, reducing endothelial cell oxidative stress, or modulating vascular ion channel activity.

Dose-response human trial: One study examined the dose-dependent effects of (–)-epicatechin on human vascular function with concurrent measurement of plasma (–)-epicatechin metabolites and levels of circulating nitrite and nitrate species. An acute, double-blind, placebo-controlled, crossover intervention trial was conducted in 20 healthy males with 4 treatment arms: water-based (–)-epicatechin at 0.1, 0.5, and 1.0 mg/kg body weight, and water only as control. Vascular function was assessed by flow-mediated dilatation (FMD) at the brachial artery. The minimum effective dose of (–)-epicatechin to induce significant physiological effects remains an important remaining challenge.

Null and mixed findings: The reported effects of flavanol-rich foods such as cocoa, dark chocolate, and apples on blood pressure and endothelial function may be due to the monomeric flavanols [mainly (–)-epicatechin], the oligomeric flavanols (procyanidins), or other components. Reports of well-controlled intervention studies that test the effects of isolated oligomeric flavanols on biomarkers of cardiovascular health are lacking. This underscores the difficulty of isolating epicatechin's specific contribution.

Animal model evidence: It has been shown to improve endothelial function in animals and humans. In salt-sensitive animal models of hypertension, epicatechin lowers blood pressure and the associated end-organ damage. In studies of chronic treatment with epicatechin on blood pressure, endothelial function, and oxidative status in DOCA-salt-induced hypertension, rats were treated for 5 weeks with (–)-epicatechin at 2 or 10 mg/kg/day. The high dose of epicatechin prevented both the increase in systolic blood pressure and the proteinuria induced by DOCA-salt. Plasma endothelin-1 and malondialdehyde levels and urinary iso-prostaglandin F2α excretion were increased in animals of the DOCA-salt group and reduced by the epicatechin 10 mg/kg treatment.

Cardioprotection: Flavanoids can act as antioxidants and inhibit platelet adhesion, low-density lipoprotein oxidation, inflammation, reactive oxygen species generation, eicosanoid synthesis, and improve insulin resistance. In humans, the ingestion of (–)-epicatechin causes vasodilatation and reproduces the antioxidant and insulin sensitizing effects of cocoa. In rodent models of ischemia-reperfusion injury, (–)-epicatechin pre-treatment showed a significant reduction in infarct size that was sustained up to 3 weeks after injury. Reductions in infarct size were accompanied by preserved myocardial inflammation, decreases in matrix metalloproteinase activity, and tissue oxidative stress. These findings are preclinical and have not been directly replicated in human cardiac trials.

Evidence strength (cardiovascular): Moderate-to-good for endothelial function improvement in human studies involving cocoa flavanols (which contain epicatechin among multiple bioactives); weaker for isolated epicatechin, where dose-response data is limited. Blood pressure effects in RCTs are consistent but effect sizes are generally modest. Much of the mechanistic evidence for cardioprotection beyond blood pressure derives from animal and in vitro data.

6.2 Skeletal Muscle Function and Muscular Dystrophies

Human clinical trial – healthy adults (grip strength and myostatin): In humans, ingestion of 1 mg/kg of bodyweight of (–)-epicatechin for 7 days increased bilateral grip strength by roughly 7% and demonstrated a favorable change in the follistatin-to-myostatin ratio.

Human clinical trial – sedentary adults (myostatin/follistatin): In the first human clinical trial examining this relationship, Gutierrez-Salmean and colleagues (2014) administered epicatechin 1 mg/kg/day to sedentary adults. They observed a 16.6% reduction in myostatin levels and a 49.2% increase in follistatin (myostatin's natural inhibitor). This study, published in the Journal of Nutritional Biochemistry, demonstrated that epicatechin myostatin modulation occurred even without concurrent exercise intervention. This pilot study had significant limitations including a small, uncontrolled design.

Human RCT – resistance-trained men: McDonald et al. (2021) conducted a randomized controlled trial with 40 resistance-trained men supplementing with 200 mg daily of epicatechin for 8 weeks, reporting a 17.8% reduction in myostatin levels with corresponding improvements in strength.

Human study – cycling exercise (negative/mixed findings): Blood and muscle samples were obtained at rest before and after training to determine the effects of (–)-epicatechin supplementation on total serum antioxidant capacity, skeletal muscle mitochondrial protein content, and skeletal muscle myostatin gene expression. Participants (n = 20) completed two testing sessions separated by 4 weeks of cycle training, with supplementation of 100 mg (200 mg total daily) of (–)-epicatechin or a placebo, twice daily. A significant increase was observed for time for relative peak anaerobic power (p < 0.01), relative anaerobic capacity (p < 0.01), and fatigue index (p < 0.01). A significant increase was also observed for absolute peak VO₂ (p < 0.01) and peak power output. A significant interaction between group and time for relative peak VO₂ was observed (p = 0.04), raising the possibility that epicatechin may have inhibited some aerobic adaptations.

Systematic review conclusions (skeletal muscle): Epicatechin is a polyphenol compound that promotes skeletal muscle differentiation and counteracts the pathways that participate in the degradation of proteins. However, several studies present contradictory results of treatment protocols and therapeutic effects. Conducting rigorous clinical studies with controlled and randomized designs is imperative to achieve more accurate therapeutic efficacy of epicatechin in humans.

Becker Muscular Dystrophy (BMD) – clinical trial: (-)-Epicatechin was evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients in a proof-of-concept Phase 1/2a pilot and endpoint development study designed to provide initial evidence of biological activity. An open-label proof-of-concept pilot study of oral epicatechin 50 mg twice daily (100 mg total per day) was conducted in ambulatory adults with genetically confirmed Becker muscular dystrophy. (-)-Epicatechin treatment significantly improved hand-grip strength and increased the ratio of follistatin to myostatin in the plasma. These proof-of-concept clinical results suggest that (–)-epicatechin may be a useful therapy for the progressive loss of muscle function.

Heart failure and type 2 diabetes – pilot: Epicatechin is an antioxidant from the flavonoid family that mimics the effects of aerobic exercise and may therefore induce mitochondrial biogenesis. A pilot study in people with heart failure or type 2 diabetes for 8 weeks showed that epicatechin helped restore markers of mitochondrial biogenesis, muscle growth, and muscle regeneration.

Evidence strength (muscle): Preliminary to moderate in humans. Several small, often uncontrolled studies support changes in the myostatin/follistatin ratio and grip strength, but the clinical relevance of these biomarker changes to meaningful gains in muscle mass in healthy individuals is not established. Evidence from animal models is more consistent. Translation from animal myostatin blockade findings to humans has generally been disappointing across pharmacological myostatin inhibitors. Clinical studies investigating the use of pharmaceutical myostatin inhibitors for stimulating muscle growth have yielded underwhelming outcomes, and several recent research analyses conclude that animal models of myostatin blockade simply haven't translated to human models.

6.3 Metabolic Health and Type 2 Diabetes

Emerging evidence supports a beneficial action of (–)-epicatechin (EC) on insulin sensitivity and potential impact on the development/progression of type 2 diabetes (T2D). In humans, supplementation with EC-rich foods, extracts, and pure EC improves insulin sensitivity and glucose tolerance in normal weight, overweight, obese, and T2D individuals. These effects are also observed in rodent models of diet-induced obesity and T2D.

Epicatechin supplementation improved insulin resistance and fasting serum insulin levels in a clinical study but had no effect on fasting blood glucose levels. In humans, the ingestion of (–)-epicatechin causes vasodilatation and reproduces the antioxidant and insulin sensitizing effects of cocoa.

Evidence strength (metabolic): Moderate, supported by multiple human studies and mechanistic rodent studies, but most human research has used cocoa flavanol mixtures rather than isolated epicatechin, making attribution difficult. Effects on fasting blood glucose appear modest.

6.4 Cognitive Function and Neurological Health

(–)-Epicatechin has been shown to modify metabolic profile, blood's rheological properties, and to cross the blood–brain barrier. Thus, (–)-epicatechin causes multiple actions that may provide unique synergy beneficial for cardiovascular and neuropsychological health.

A detailed review of human intervention studies on epicatechin and cognition found the following: the positive modulation of tasks that involve memory, executive function and processing speed in older adults; the cognitive benefits are more often shown in studies containing more than 50 mg epicatechin/day; and all studies with a duration of 28 days or longer in populations >50 years old demonstrate a cognitive improvement. However, it is not currently possible to attribute effects solely to epicatechin without consideration of synergies.

The Paquid longitudinal study demonstrated that the relative risk of dementia was significantly lower for those in the two highest tertiles of flavonoid consumption compared to those in the lowest tertile when followed up 5 years later. Analysis of neuropsychological function revealed a significant positive association between flavonoid consumption and task performance. An inverse relationship between intake and cognitive decline over the 10-year follow-up was also demonstrated, whereby those in the highest two quartiles of flavonoid intake had less cognitive decline than those in the lowest quartile.

Evidence strength (cognitive): Preliminary for epicatechin specifically. Most positive human data come from flavonoid-rich food interventions (cocoa, dark chocolate) rather than isolated epicatechin supplementation. The cross-blood–brain barrier property is established, but whether this translates to meaningful clinical cognitive benefit in healthy populations remains under investigation.

6.5 Anti-Inflammatory Effects

Recent studies have shown that EC protects human health and exhibits prominent anti-oxidant and anti-inflammatory activities, enhances muscle performance, improves symptoms of cardiovascular and cerebrovascular diseases, prevents diabetes, and protects the nervous system.

By mitigating NOX4-driven oxidative stress, EC effectively prevented the shift from the anti-inflammatory M2 phenotype to the pro-inflammatory M1 phenotype, ultimately disrupting the cycle of macrophage-driven adipose tissue inflammation. Inflammation has been linked to cancer development, progression, invasion, and metastasis, and the use of anti-inflammatory agents has been proposed as an attractive adjunct therapy; application of (–)-epicatechin may be such a viable approach.

Evidence strength (anti-inflammatory): Primarily mechanistic and preclinical. Human clinical trials specifically targeting inflammatory endpoints with isolated epicatechin are limited.

6.6 Cancer – Preclinical and Emerging Evidence

(–)-Epicatechin was shown to cause DNA damage and apoptosis in acute myeloid leukemia cells in rats when administered orally at a dose of 40 mg/kg body weight for 22 consecutive days. Additionally, (–)-epicatechin was shown to inhibit the proliferation of Hodgkin's lymphoma cells and Jurkat T cells, which was attributed to the ability of (–)-epicatechin to inhibit the binding of NF-κB to DNA in these cells.

Evidence strength (cancer): Almost entirely preclinical (cell culture and animal data). No human clinical trials have examined epicatechin as a cancer treatment. This evidence should not be interpreted as demonstrating efficacy in humans.

7. Pharmacokinetics and Bioavailability

A landmark study using radiolabeled (–)-epicatechin established that 82 ± 5% of ingested EC was absorbed, and pharmacokinetic profiles and over 20 different metabolites were identified and quantified.

(–)-Epicatechin undergoes substantial metabolism into structurally related (–)-epicatechin metabolites before entering the circulation, which may or may not alter its function. The role of the gut microbiome in the metabolism of EC in humans has only recently been recognized, increasing the complexity of the EC metabolome.

Key dietary intervention studies using flavanol-containing foods provided an intake of EC ranging from 90–203 mg/day. The habitual population-based intake of flavanol monomers (catechin/epicatechin) is reported as averaging 24 or 45 mg per day, indicating that intakes of 60 mg/day are directly applicable in the context of habitual dietary intake and clinical dietary investigations.

In the pharmacokinetic study with (–)-epicatechin in healthy volunteers, it was well tolerated over the 50–200 mg dose range, with rapid absorption and first-pass metabolism. (–)-Epicatechin and its metabolites were rapidly cleared from the body with a plasma elimination half-life of approximately 2.5 hours for the 100 and 200 mg doses.

It is concluded that epicatechins are poorly absorbed in humans by some analyses, though this conclusion conflicts with the radiolabeled study finding of 82% absorption, illustrating that estimates vary substantially based on methodology and whether metabolites are measured.

8. Dosages Reported in Studies

The following dosages are those specifically reported in the cited research literature:

• 1 mg/kg/day: Used in the Gutierrez-Salmean et al. (2014) study examining myostatin/follistatin changes in sedentary adults; also associated with a 7% increase in bilateral grip strength after 7 days.
• 50 mg twice daily (100 mg/day): Used in the Becker Muscular Dystrophy pilot study for 8 weeks.
• 100 mg twice daily (200 mg/day): Used in the Schwarz et al. (2018) cycling exercise study over 4 weeks in 20 participants.
• 200 mg/day: Used in the McDonald et al. (2021) RCT with 40 resistance-trained men for 8 weeks.
• 0.1, 0.5, and 1.0 mg/kg body weight (acute): Used in a double-blind, placebo-controlled, crossover trial in 20 healthy males examining vascular function.
• 50–200 mg: Range evaluated in the pharmacokinetic (PK) safety study, in which (–)-epicatechin was well tolerated.
• 2 or 10 mg/kg/day: Used in the DOCA-salt animal hypertension model, in which the high dose prevented increases in systolic blood pressure.

9. Safety, Tolerability, and Drug Interactions

General Tolerability

Animal and human safety studies suggest that (–)-epicatechin at doses of 1–2 mg/kg should be safe and well tolerated. In a study with green tea extracts containing (–)-epicatechin given orally to rats daily for 6 months, the no-observable-adverse-effect level (NOAEL) corresponded to 85 mg (–)-epicatechin/kg. For the human dosing plan of 1 mg/kg, this provides a safety margin relative to the rat NOAEL of at least 85-fold.

The dosing plan is also supported by published human studies, in which (–)-epicatechin doses of 1 and 2 mg/kg were administered with no adverse events reported.

Purified (–)-epicatechin has shown good tolerability in limited human research, but supplement safety depends on source material, purity, serving level, co-ingredients, individual health status, claims, and documentation quality.

Potential Risks and Adverse Effects

Potential risks based on the biological activities of (–)-epicatechin include hypotension: given the reported effects of (–)-epicatechin on blood vessels, it is reasonable to assume that a potential risk may be associated with vasodilation.

Some epicatechin products also contain caffeine, green tea extract, EGCG, piperine, nitric oxide support ingredients, stimulant-like compounds, or other botanical extracts. In these cases, digestive discomfort, dizziness, liver-health concerns, or medication interaction considerations may be related to the full formula rather than epicatechin alone.

Multi-Ingredient Formulation Considerations

Not all "epicatechin" ingredients are the same. Safety review should distinguish between purified (–)-epicatechin powder, cocoa flavanol extracts, green tea extracts, EGCG-rich extracts, multi-catechin blends, and finished products that include caffeine or bioavailability enhancers.

Long-Term Safety Data

Long-term safety studies addressing the current knowledge gap regarding chronic epicatechin consumption are underway at several research institutions. These studies, following participants for 12–24 months, will provide insight into potential cumulative side effects not detectable in shorter interventions. Preliminary data from these studies suggests favorable long-term tolerability, though complete results remain pending.

Blood Pressure and Cardiovascular Considerations

Given epicatechin's established vasodilatory activity via eNOS/NO upregulation, individuals taking antihypertensive medications may warrant attention when combining with epicatechin supplements, due to additive blood pressure-lowering effects. This concern is noted in clinical trial protocols, though specific interaction pharmacokinetics in humans are not well characterized in published literature.

10. Body Systems and Health Areas

• Cardiovascular system: Epicatechin exerts beneficial effects on the cardiovascular system, including anti-atherosclerotic and anti-inflammatory activities, by modulating nitric oxide metabolism and exhibiting antioxidant properties.
• Skeletal muscle: Epicatechin is studied for its roles in endothelial NO signaling, myostatin pathway modulation, and mitochondrial function within skeletal muscle and vascular tissues.
• Metabolic/endocrine system: Emerging evidence supports a beneficial action of EC on insulin sensitivity and potential impact on the development/progression of type 2 diabetes.
• Central nervous system/brain: (-)-Epicatechin has been shown to modify metabolic profile, blood's rheological properties, and to cross the blood–brain barrier.
• Immune and inflammatory pathways: EC acts via suppression of NF-κB, MAPK, and JAK/STAT inflammatory pathways, and through activation of Nrf2-driven antioxidant responses that mitigate inflammatory damage.
• Vascular endothelium: Epicatechin seems to be a major bioactive constituent of cocoa and other flavanol-rich foods and beverages, and it has been shown to improve endothelial function in animals and humans.

References

• ScienceDirect Topics: Epicatechin – Overview (Beer in Health and Disease Prevention, 2009)
• Holt RR et al. (2012). Epicatechin: Endothelial Function and Blood Pressure. Journal of Agricultural and Food Chemistry.
• Gomez-Guzman M et al. (2012). Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radical Biology and Medicine.
• Rodriguez-Mateos A et al. (2018). Biological activities of (−)-epicatechin and (−)-epicatechin-containing foods: Focus on cardiovascular and neuropsychological health. Biotechnology Advances.
• Cremonini E et al. (2019). (–)-Epicatechin in the control of glucose homeostasis: Involvement of redox-regulated mechanisms. Free Radical Biology and Medicine.
• Crichton GE & Elias MF (2018). The Impact of Epicatechin on Human Cognition: The Role of Cerebral Blood Flow. Nutrients. PMC6115745.
• Rodrigues R et al. (2024). New Trends to Treat Muscular Atrophy: A Systematic Review of Epicatechin. Nutrients. PMC10818576.
• Schwarz NA et al. (2018). (–)-Epicatechin Supplementation Inhibits Aerobic Adaptations to Cycling Exercise in Humans. Frontiers in Nutrition. PMC6308990.
• Ottaviani JI et al. (2016). The metabolome of [2-14C](−)-epicatechin in humans: implications for the assessment of efficacy, safety and mechanisms of action of polyphenolic bioactives. Scientific Reports.
• Barnett CF et al. (2015). Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers. Food & Function. PMC4357542.
• Yamazaki KG et al. (2010). Effects of (−)-epicatechin on myocardial infarct size and left ventricular remodeling following permanent coronary occlusion. Journal of the American Heart Association. PMC2915587.
• Malhotra A et al. (2015). Molecular Mechanisms and Therapeutic Effects of (−)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, and Neurodegeneration. Oxidative Medicine and Cellular Longevity. PMC4477097.
• (-)-Epicatechin and inflammation: Unraveling the role of microbial metabolites and interindividual metabolic variability. Frontiers in Nutrition. PMC13057332.
• Tomaniak M et al. (2021). Phenolic Bioactives as Antiplatelet Aggregation Factors. Nutrients. PMC8384526.
• Qu Z et al. (2021). Advances in physiological functions and mechanisms of (−)-epicatechin. Critical Reviews in Food Science and Nutrition. PubMed 32090598.
• Prickett CD et al. (2022). Lack of acute or chronic effects of epicatechin-rich and procyanidin-rich apple extracts on blood pressure and cardiometabolic biomarkers in adults with moderately elevated blood pressure. American Journal of Clinical Nutrition.
• Acute study of dose-dependent effects of (−)-epicatechin on vascular function in healthy male volunteers. Clinical Nutrition.
• ClinicalTrials.gov NCT01856868: Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study) – Study Protocol.
• ClinicalTrials.gov NCT02964377: Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents – Study Protocol.
• Institut de Myologie (2020). Epicatechin appears to be of short-term benefit in Becker's myopathy.
• Wikipedia: Catechin – distribution and food sources.